The Potential Impact of Adding Genetic Markers to Clinical Parameters in Managing High-risk Prostate Cancer Patients

Overview

Journal Springerplus

Date 2013 Sep 19

PMID 24046815

Authors

Maria Jesus Alvarez-Cubero

Luis Javier Martinez-Gonzalez

Fernando Vazquez-Alonso

Maria Saiz

Juan Carlos Alvarez

Jose Antonio Lorente

Jose Manuel Cozar

Affiliations

Soon will be listed here.

Abstract

Purpose: High-risk prostate cancer is a potentially lethal disease that is increasing in the diagnosis of prostate cancer patients. Compared to other prostate cancer patients (medium or low risk), management, diagnosis and treatment are not as successful among high-risk patients. Because the genetic characterization of prostate cancer patients is increasing, we aimed to determine whether genetic information in one of the primary associated genes, such as RNASEL (2', 5'-oligoadenylate-dependent RNase L), could be used as a biomarker to improve the quality of life and treatment among high-risk patients. The main objective is to identify genetic variants of RNASEL that could be associated with high-risk prostate cancer to improve the clinical managing of these patients.

Methods: A total of 231 prostate cancer patients were genotyped for 7 variants of RNASEL gene. Clinical information was obtained from medical examinations and genetic analysis (amplification and sequencing 7 variants of RNASEL gene) were performed by the researchers. Data were processed by statistical analysis (Chi square and logistic regression) using SPSS v.15.0.

Results: Comparisons between genotypes and clinical characteristics of patients revealed that individuals with GG in D541E, AA in R462Q and AG in I97L in RNASEL gene were high-risk patients according to the European Urology Guidelines.

Conclusions: Genotyping the RNASEL gene with routine diagnostic techniques could confer a more precise diagnosis of high-risk prostate cancer patients and increase the diagnostic accuracy above the current rate of 70% due to the relation between the genetic variants of RNASEL gene and the risk of this cancer.

References

Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen H, Kattan M . Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol. 2005; 174(6):2158-63. DOI: 10.1097/01.ju.0000181224.95276.82. View

Dorff T, Flaig T, Tangen C, Hussain M, Swanson G, Wood Jr D . Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011; 29(15):2040-5. PMC: 3107759. DOI: 10.1200/JCO.2010.32.2776. View

Bastian P, Boorjian S, Bossi A, Briganti A, Heidenreich A, Freedland S . High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012; 61(6):1096-106. DOI: 10.1016/j.eururo.2012.02.031. View

Masterson T, Touijer K . The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA. 2008; 21(6):371-7. DOI: 10.1007/s10334-008-0116-4. View

Smith Jr J, Scardino P, Resnick M, Hernandez A, Rose S, Egger M . Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol. 1997; 157(3):902-6. View

Rinnab L, Blumstein N, Mottaghy F, Hautmann R, Kufer R, Hohl K . 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int. 2007; 99(6):1421-6. DOI: 10.1111/j.1464-410X.2007.06776.x. View

Excoffier L, Lischer H . Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 2011; 10(3):564-7. DOI: 10.1111/j.1755-0998.2010.02847.x. View

Jager G, Severens J, THORNBURY J, de la Rosette J, Ruijs S, Barentsz J . Prostate cancer staging: should MR imaging be used?--A decision analytic approach. Radiology. 2000; 215(2):445-51. DOI: 10.1148/radiology.215.2.r00ap09445. View

Marciscano A, Hardee M, Sanfilippo N . Management of high-risk localized prostate cancer. Adv Urol. 2011; 2012:641689. PMC: 3206331. DOI: 10.1155/2012/641689. View

10.

DAmico A, Chen M, Renshaw A, Loffredo M, Kantoff P . Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299(3):289-95. DOI: 10.1001/jama.299.3.289. View

11.

Casey G, Neville P, Plummer S, Xiang Y, Krumroy L, Klein E . RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002; 32(4):581-3. DOI: 10.1038/ng1021. View

12.

Shook S, Beuten J, Torkko K, Johnson-Pais T, Troyer D, Thompson I . Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res. 2007; 13(19):5959-64. DOI: 10.1158/1078-0432.CCR-07-0702. View

13.

Meyer M, Penney K, Stark J, Schumacher F, Sesso H, Loda M . Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010; 31(9):1597-603. PMC: 2930803. DOI: 10.1093/carcin/bgq132. View

14.

Alvarez-Cubero M, Entrala C, Fernandez-Rosado F, Martinez-Gonzalez L, Alvarez J, Suarez A . Predictive value in the analysis of RNASEL genotypes in relation to prostate cancer. Prostate Cancer Prostatic Dis. 2011; 15(2):144-9. DOI: 10.1038/pcan.2011.56. View

15.

Agalliu I, Leanza S, Smith L, Trent J, Carpten J, Bailey-Wilson J . Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate. 2010; 70(15):1716-27. PMC: 3404133. DOI: 10.1002/pros.21207. View